Silo Pharma Secures Japanese Patent For PTSD Therapy SPC-15, Licensed From Columbia University, Expanding Global IP Portfolio

Silo Pharma, Inc., a diversified biopharmaceutical and cryptocurrency treasury company, announced that the Japan Patent Office has granted patent number 7683882 to its research and licensing partner, Columbia University. The patent, titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress,” has been exclusively licensed to Silo by Columbia University. This follows a recent Australian patent granted to Columbia for the same invention.

The newly issued patent strengthens intellectual property protection around Silo’s lead asset, SPC-15, an intranasal therapy being developed for the treatment of post-traumatic stress disorder (PTSD). SPC-15 was originally developed by Columbia University and is a central focus of Silo’s pipeline.

According to Eric Weisblum, Chief Executive Officer of Silo Pharma, the Japanese patent provides an additional layer of protection for SPC-15 and further expands the company’s international patent portfolio. He added that this growing intellectual property base will play a key role in advancing both the development and regulatory strategy of Silo’s novel PTSD therapy.